Capricor Therapeutics’ CAP-1002: Regulatory Progress, Clinical Outcomes & Investment Outlook
Regulatory Status of CAP-1002 (Deramiocel) Biologics License Application (BLA) Progress: Capricor’s lead therapy CAP-1002 (generic name Deramiocel) is under active FDA review for Duchenne muscular dystrophy (DMD) cardiomyopathy. The BLA was accepted in …